Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
V VARIOUS
V03 ALL OTHER THERAPEUTIC PRODUCTS
V03A ALL OTHER THERAPEUTIC PRODUCTS
V03AX Other therapeutic products
V03AX02 Nalfurafine
D06405 Nalfurafine hydrochloride (JAN/USAN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D06405 Nalfurafine hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01564 Opioid receptor agonist
DG01562 kappa-Opioid receptor agonist
D06405 Nalfurafine hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D06405 Nalfurafine hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Opioid
OPRK1
D06405 Nalfurafine hydrochloride (JAN/USAN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06405
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06405
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D06405